CATALYSIS Advises Vascular Device Company Vascular Flow Technologies Limited on a Combined £10.0 Million Series A and Series B Financing

/in /by

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Vascular Flow Technologies Limited on the restructuring of £7,000,000 in outstanding loan notes into Series A Ordinary Preference shares as well as the concurrent closing of a £3,000,000 Series B financing round. The Series B round was led by an undisclosed family office and supported by institutional and individual angel investors.

Vascular Flow Technologies (Dundee, United Kingdom) is focused on the research, development and commercialisation of devices to improve blood flow in compromised or diseased blood vessels utilizing its proprietary Spiral Laminar Flow technology. Natural blood flow has a distinctive singular spiral flow pattern and the patented Spiral Laminar Flow technology is the only clinically‐proven design to replicate this. The Company has two CE-marked and FDA approved devices commercialised in Europe and the US. The Spiral Laminar Flow technology is used to create a longer lasting graft or stent, producing a better quality-of-life for the patient due to reduced vascular complications and improved longevity of the implant. Further information is available at www.vascular‐flow.com.

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK

CATALYSIS Advises Dermatology Diagnostic Imaging Company Michelson Diagnostics Limited on £1.5 Million Financing

/in /by

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series C financing raising £1,500,000. The round was led by Octopus Investments and supported by Smith & Nephew, Kent County Council and several individual angel investors.

Michelson Diagnostics (Kent, United Kingdom) develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (‘OCT’) scanner; a point-of-care, real-time tissue imaging device. The patented technology, which has CE/TGA regulatory clearance and FDA 510(k) approval in the United States, provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a medical professional. Given the unprecedented image resolution and image quality, VivoSight OCT has many potential clinical applications beyond the initial focus in dermatology. The Company’s vision is for the VivoSight OCT system to become the standard-of-care for the non-invasive diagnosis and treatment monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. Michelson Diagnostics currently generates revenues from the first commercial application of VivoSight, in the diagnosis of non-melanoma skin cancer (NMSC). For more information visit www.michelsondiagnostics.com or www.vivosight.com.

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK

CATALYSIS Advises Dermatology Diagnostic Imaging Company Michelson Diagnostics Limited on £2.5 Million Financing

/in /by

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series D financing raising £2,500,000. The round was led by Smith & Nephew and Kent County Council and supported by Octopus Investments and several individual angel investors.

Michelson Diagnostics (Kent, United Kingdom) develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (‘OCT’) scanner; a point-of-care, real-time tissue imaging device. The patented technology, which has CE/TGA regulatory clearance and FDA 510(k) approval in the United States, provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a medical professional. Given the unprecedented image resolution and image quality, VivoSight OCT has many potential clinical applications beyond the initial focus in dermatology. The Company’s vision is for the VivoSight OCT system to become the standard-of-care for the non-invasive diagnosis and treatment monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. Michelson Diagnostics currently generates revenues from the first commercial application of VivoSight, in the diagnosis of non-melanoma skin cancer (NMSC). For more information visit www.michelsondiagnostics.com or www.vivosight.com.

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK

CATALYSIS Advises Dermatology Diagnostic Imaging Company Michelson Diagnostics Limited on £1.98 Million Financing

/in /by

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series A2 financing raising £1,977,779. The round was led by Octopus Investments and supported by Catapult Venture Managers Ltd, London Business Angels and several individual angel investors.

Michelson Diagnostics Ltd. (Orpington, United Kingdom) is a privately held diagnostic imaging company focused on the diagnosis and treatment-management of non-melanoma skin cancer (“NMSC”).  The Company product, VivoSight® OCT, is a diagnostic imaging device using multi-beam optical coherence tomography (“OCT”), enabling dermatologists to produce a real-time, continuous high-resolution scanned images up to 2 millimetres beneath the surface of the skin.  This revolutionary technology offers a viable alternative to biopsies as it allows dermatologists to diagnose and discuss treatment-options with patients in a single visit, thus offering improved clinical outcomes, healthcare economics and patient experience.  Moreover, VivoSight® enables dermatologists to consider topical therapeutic options as an alternative to excising the NMSC lesion by ensuring in a follow-up scan that this treatment course has been successful. For more information visit www.michelsondiagnostics.com or www.vivosight.com

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.

CATALYSIS Advises Orphan Oncology Company ERYTECH Pharma SA on €5.0 Million Convertible Note

/in /by

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to ERYTECH Pharma SA in securing  €5.0 million from Recordati in the form of a convertible note.  The transaction was concurrent with ERYTECH Pharma signing a licensing and distribution agreement with Orphan Europe for GRASPA® in Europe.  Orphan Europe is part of the Recordati Group. Read more →